| [1] |
Stohr K. Influenza--WHO cares[J]. Lancet Infect Dis,2002,2(9):517.
|
| [2] |
Lin J, Kang M, Zhong H, et al. Influenza seasonality and predominant subtypes of influenza virus in Guangdong, China, 2004-2012[J]. J Thorac Dis,2013,5(2):109-117.
|
| [3] |
Peng Z, Feng L, Carolyn GM, et al. Characterizing the epidemiology, virology, and clinical features of influenza in China’s first severe acute respiratory infection sentinel surveillance system, February 2011-October 2013[J]. BMC Infect Dis,2015,15(1):143.
|
| [4] |
Cheng X, Tan Y, He M, et al. Epidemiological dynamics and phylogeography of influenza virus in southern China[J]. J Infect Dis,2013, 207(1):106-114.
|
| [5] |
中国国家流感中心. 2018第02周流感周报[EB/OL].
URL
|
| [6] |
宋祎凡. 世界卫生组织关于2015-2016年北半球流行性感冒流行季节流行性感冒疫苗组成成分的推荐意见[J]. 中国疫苗和免疫,2015,21(3):277.
|
| [7] |
Morens DM, Taubenberger JK. Influenza Cataclysm, 1918[J]. N Engl J Med,2018,379(24):2285-2287.
|
| [8] |
Oxford JS. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology[J]. Rev Med Virol,2000,10(2):119-133.
|
| [9] |
Christensen D, Christensen JP, Korsholm KS, et al. Seasonal influenza split vaccines confer partial cross-protection against heterologous influenza virus in ferrets when combined with the CAF01 adjuvant[J]. Front Immunol,2018,8:1928.
|
| [10] |
Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines[J]. Hum Vaccin Immunother,2012,8(1):81-88.
|
| [11] |
Ampofo WK, Azziz-Baumgartner E, Bashir U, et al. Strengthening the influenza vaccine virus selection and development process: report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014[J]. Vaccine,2015,33(36):4368-4382.
|
| [12] |
Barberis I, Myles P, Ault SK, et al. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines[J]. J Prev Med Hyg,2016,57(3):E115-E120.
|
| [13] |
Bart S, Cannon K, Herrington D, et al. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a Phase Ⅲ, doubleblind, multicenter, randomized, non-inferiority study[J]. Hum Vaccin Immunother,2016,12(9):2278-2288.
|
| [14] |
Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children[J]. Pediatr Infect Dis J,2011,30(12):1081-1085.
|
| [15] |
de Jong JC, Palache AM, Beyer WE, et al. Haemagglutination-inhibiting antibody to influenza virus[J]. Dev Biol (Basel),2003,115:63-73.
|
| [16] |
Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years[J]. J Infect Dis,2013,207(12):1878-1887.
|
| [17] |
Englund JA, Walter EB, Gbadebo A, et al. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers[J]. Pediatrics,2006,118(3):e579-e585.
|
| [18] |
Glezen WP, Couch RB, Taber LH, et al. Epidemiologic observations of influenza B virus infections in Houston, Texas, 1976-1977[J]. Am J Epidemiol,1980,111(1):13-22.
|
| [19] |
Glezen WP, Schmier JK, Kuehn CM, et al. The burden of influenza B: a structured literature review[J]. Am J Public Health,2013,103(3):e43-e51.
|
| [20] |
Greenberg DP, Robertson CA, Landolfi VA, et al. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age[J]. Pediatr Infect Dis J,2014,33(6):630-636.
|
| [21] |
Hartvickson R, Cruz M, Ervin J, et al. Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to Journal Pre-proof trivalent subunit influenza virus vaccines in healthy children: a phase Ⅲ randomized, multicenter, double-blind clinical trial[J]. Int J Infect Dis,2015,41:65-72.
|
| [22] |
You JH, Ming WK, Chan PK. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong--a decision analysis[J]. Hum Vaccin Immunother,2015,11(3):564-571.
|